Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy
- PMID: 11136352
- DOI: 10.1046/j.1468-1331.2000.00111.x
Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy
Abstract
Six patients with idiopathic Parkinson's disease (IPD), six with clinically probable multiple system atrophy and six control subjects underwent quantitative proton magnetic resonance spectroscopy (MRS). The concentrations of the three major metabolites, N-acetylaspartate (NAA), creatine and choline, were quantified in the lentiform nucleus using tissue water content as an internal concentration reference. Glutamate was assessed as the (glutamate + glutamine)/creatine peak area ratio (Glx/Cre). In the control subjects the mean (+/- SD) concentrations of the three metabolites were 15.2 +/- 2.9 micromol/g wet weight for NAA, 12.0 +/- 1.4 for creatine and 2.4 +/- 0.3 for choline. The Glx/Cre ratio was 1.28 +/- 0.32. The only significant difference in any metabolite concentration was in the lentiform nucleus of patients with IPD compared with controls, with an increase in choline which lead to a significant reduction in the NAA/choline ratio. The relevance of this finding is uncertain. The results of the present pilot study, combined with the conflicting findings from previous work, suggest that further, much larger, studies are required to evaluate the diagnostic capability of proton MRS.
Similar articles
-
Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy.Mov Disord. 1997 May;12(3):297-301. doi: 10.1002/mds.870120306. Mov Disord. 1997. PMID: 9159722
-
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.Ann Neurol. 1995 Feb;37(2):204-10. doi: 10.1002/ana.410370211. Ann Neurol. 1995. PMID: 7847862
-
Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes.Ital J Neurol Sci. 1999 Aug;20(4):223-9. doi: 10.1007/s100720050035. Ital J Neurol Sci. 1999. PMID: 10551908
-
Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.Autism Res. 2013 Apr;6(2):119-33. doi: 10.1002/aur.1273. Epub 2013 Feb 21. Autism Res. 2013. PMID: 23436782 Review.
-
Proton magnetic resonance spectroscopy of the human brain in schizophrenia.Rev Neurosci. 2000;11(2-3):147-58. doi: 10.1515/revneuro.2000.11.2-3.147. Rev Neurosci. 2000. PMID: 10718151 Review.
Cited by
-
Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):103-9. J Neurol Neurosurg Psychiatry. 2004. PMID: 14707317 Free PMC article. Clinical Trial.
-
Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.Front Neurol. 2022 Jun 16;13:838230. doi: 10.3389/fneur.2022.838230. eCollection 2022. Front Neurol. 2022. PMID: 35785357 Free PMC article.
-
Aberrant regulation of choline metabolism by mitochondrial electron transport system inhibition in neuroblastoma cells.Metabolomics. 2008 Dec 1;4(4):347-356. doi: 10.1007/s11306-008-0125-3. Metabolomics. 2008. PMID: 19774105 Free PMC article.
-
Brain MR Contribution to the Differential Diagnosis of Parkinsonian Syndromes: An Update.Parkinsons Dis. 2016;2016:2983638. doi: 10.1155/2016/2983638. Epub 2016 Sep 28. Parkinsons Dis. 2016. PMID: 27774334 Free PMC article. Review.
-
MR spectroscopy in neurodegenerative disease.Mol Imaging Biol. 2007 Jul-Aug;9(4):196-203. doi: 10.1007/s11307-007-0087-2. Mol Imaging Biol. 2007. PMID: 17279431 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical